{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:43:45Z","timestamp":1784202225565,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011199","name":"FP7 Ideas: European Research Council","doi-asserted-by":"publisher","award":["Consolidator Grant MODEST-647573"],"award-info":[{"award-number":["Consolidator Grant MODEST-647573"]}],"id":[{"id":"10.13039\/100011199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012320","name":"Otto-von-Guericke-Universit\u00e4t Magdeburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Infections due to severe neutropenia are the most common therapy-associated causes of mortality in patients with acute myeloid leukemia (AML). New strategies to lessen the severity and duration of neutropenia are needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cytarabine is commonly used for AML consolidation therapy; we compared high- and intermediate-dose cytarabine administration on days 1, 2, and 3 (AC-123) versus days 1, 3, and 5 (AC-135) in consolidation therapy of AML. Recently, clinical trials demonstrated that high-dose AC-123 resulted in a shortened white blood cell (WBC) recovery time compared with high-dose AC-135. Our main hypothesis is that this is also the case for different cytarabine dosage, granulocyte colony-stimulating factor (G-CSF) administration, and cycle lengths. We analyzed 334 treatment schedules on virtual cohorts of digital twins.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Comparison of 32,565 simulated consolidation cycles resulted in a reduction in the WBC recovery time for AC-123 in 99.6% of the considered cycles (median reduction 3.5 days) without an increase in the number of leukemic blasts (lower value in 94.2% of all cycles), compared to AC-135.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our numerical study supports the use of AC-123 plus G-CSF as standard conventional AML consolidation therapy to reduce the risk for life-threatening infectious complications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-05115-0","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T15:02:05Z","timestamp":1691074925000},"page":"13811-13821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["AML consolidation therapy: timing matters"],"prefix":"10.1007","volume":"149","author":[{"given":"Adrian-Manuel","family":"Reimann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mougiakakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ditzhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Sager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"issue":"2","key":"5115_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","volume":"64","author":"GP Bodey","year":"1966","unstructured":"Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328\u2013340. https:\/\/doi.org\/10.7326\/0003-4819-64-2-328","journal-title":"Ann Intern Med"},{"issue":"10","key":"5115_CR2","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1007\/s11538-019-00640-x","volume":"81","author":"R Brady","year":"2019","unstructured":"Brady R, Enderling H (2019) Mathematical models of cancer: when to predict novel therapies, and when not to. Bull Math Biol 81(10):3722\u20133731. https:\/\/doi.org\/10.1007\/s11538-019-00640-x","journal-title":"Bull Math Biol"},{"issue":"27","key":"5115_CR3","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BES, Wheatley K, Milligan D (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. J Clin Oncol 31(27):3360\u20133368. https:\/\/doi.org\/10.1200\/JCO.2012.47.4874","journal-title":"J Clin Oncol"},{"issue":"3","key":"5115_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40324-022-00296-z","volume":"79","author":"S Chuli\u00e1n","year":"2022","unstructured":"Chuli\u00e1n S, Mart\u00ednez-Rubio \u00c1, Rosa M, P\u00e9rez-Garc\u00eda VM (2022) Mathematical models of leukaemia and its treatment: a review. SeMA J 79(3):441\u2013486. https:\/\/doi.org\/10.1007\/s40324-022-00296-z","journal-title":"SeMA J"},{"issue":"3","key":"5115_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1051\/mmnp\/20094302","volume":"4","author":"J Clairambault","year":"2009","unstructured":"Clairambault J (2009) Modelling physiological and pharmacological control on cell proliferation to optimise cancer treatments. Math Model Nat Phenom 4(3):12\u201367. https:\/\/doi.org\/10.1051\/mmnp\/20094302","journal-title":"Math Model Nat Phenom"},{"issue":"2","key":"5115_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia. Cancer 100(2):228\u2013237. https:\/\/doi.org\/10.1002\/cncr.11882","journal-title":"Cancer"},{"issue":"4","key":"5115_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien H-F, Wei AH, L\u00f6wenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"16","key":"5115_CR8","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1182\/bloodadvances.2020002511","volume":"4","author":"P-Y Dumas","year":"2020","unstructured":"Dumas P-Y, Bertoli S, B\u00e9rard E, Leguay T, Tavitian S, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial J-P, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Rey H, de Grande A-C, Despas F, Pigneux A, R\u00e9cher C (2020) Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. Blood Adv 4(16):3840\u20133849. https:\/\/doi.org\/10.1182\/bloodadvances.2020002511","journal-title":"Blood Adv"},{"issue":"24","key":"5115_CR9","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","volume":"20","author":"LE Friberg","year":"2002","unstructured":"Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713\u20134721","journal-title":"J Clin Oncol"},{"issue":"9","key":"5115_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11912-021-01092-0","volume":"23","author":"S Jaramillo","year":"2021","unstructured":"Jaramillo S, Schlenk RF (2021) Post-induction treatment for acute myeloid leukemia: something change? Curr Oncol Rep 23(9):109. https:\/\/doi.org\/10.1007\/s11912-021-01092-0","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"5115_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/bcj.2017.45","volume":"7","author":"S Jaramillo","year":"2017","unstructured":"Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, K\u00f6hne C-H, G\u00f6tze K, L\u00fcbbert M, K\u00fcndgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst H-A, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, G\u00f6hring G, D\u00f6hner K, Ganser A, D\u00f6hner H, Schlenk RF (2017) Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J 7(5):564\u2013564. https:\/\/doi.org\/10.1038\/bcj.2017.45","journal-title":"Blood Cancer J"},{"issue":"7","key":"5115_CR12","doi-asserted-by":"publisher","first-page":"0204540","DOI":"10.1371\/journal.pone.0204540","volume":"14","author":"F Jost","year":"2019","unstructured":"Jost F, Schalk E, Rinke K, Fischer T, Sager S (2019) Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia. PLoS One 14(7):0204540. https:\/\/doi.org\/10.1371\/journal.pone.0204540","journal-title":"PLoS One"},{"issue":"12","key":"5115_CR13","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1109\/TBME.2020.2982749","volume":"67","author":"F Jost","year":"2020","unstructured":"Jost F, Schalk E, Weber D, D\u00f6hner H, Fischer T, Sager S (2020) Model-based optimal AML consolidation treatment. IEEE Trans Biomed Eng 67(12):3296\u20133306. https:\/\/doi.org\/10.1109\/TBME.2020.2982749","journal-title":"IEEE Trans Biomed Eng"},{"issue":"5","key":"5115_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cell.2015.11.002","volume":"163","author":"F Michor","year":"2015","unstructured":"Michor F, Beal K (2015) Improving cancer treatment via mathematical modeling: surmounting the challenges is worth the effort. Cell 163(5):1059\u20131063. https:\/\/doi.org\/10.1016\/j.cell.2015.11.002","journal-title":"Cell"},{"issue":"1","key":"5115_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","volume":"42","author":"L Nesher","year":"2014","unstructured":"Nesher L, Rolston KVI (2014) The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 42(1):5\u201313. https:\/\/doi.org\/10.1007\/s15010-013-0525-9","journal-title":"Infection"},{"key":"5115_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04633-1","author":"S Sager","year":"2023","unstructured":"Sager S (2023) Digital twins in oncology. J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-023-04633-1","journal-title":"J Cancer Res Clin Oncol"},{"issue":"19","key":"5115_CR17","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1200\/JCO.2010.33.7303","volume":"29","author":"M Schaich","year":"2011","unstructured":"Schaich M, R\u00f6llig C, Soucek S, Kramer M, Thiede C, Mohr B, Oelschlaegel U, Schmitz N, Stuhlmann R, Wandt H, Sch\u00e4fer-Eckart K, Aulitzky W, Kaufmann M, Bodenstein H, Tischler J, Ho A, Kr\u00e4mer A, Bornh\u00e4user M, Schetelig J, Ehninger G (2011) Cytarabine dose of 36 g\/m2 compared with 12 g\/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol 29(19):2696\u20132702. https:\/\/doi.org\/10.1200\/JCO.2010.33.7303","journal-title":"J Clin Oncol"},{"issue":"1","key":"5115_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1471-2407-8-195","volume":"8","author":"J Sierra","year":"2008","unstructured":"Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 8(1):195. https:\/\/doi.org\/10.1186\/1471-2407-8-195","journal-title":"BMC Cancer"},{"issue":"8","key":"5115_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ncponc0560","volume":"3","author":"R Simon","year":"2006","unstructured":"Simon R, Norton L (2006) The Norton\u2013Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 3(8):406\u2013407. https:\/\/doi.org\/10.1038\/ncponc0560","journal-title":"Nat Clin Pract Oncol"},{"issue":"1","key":"5115_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1051\/mmnp\/20127199","volume":"7","author":"T Stiehl","year":"2012","unstructured":"Stiehl T, Marciniak-Czochra A (2012) Mathematical modeling of leukemogenesis and cancer stem cell dynamics. Math Model Nat Phenom 7(1):166\u2013202. https:\/\/doi.org\/10.1051\/mmnp\/20127199","journal-title":"Math Model Nat Phenom"},{"issue":"1","key":"5115_CR21","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1038\/s41598-018-21115-4","volume":"8","author":"T Stiehl","year":"2018","unstructured":"Stiehl T, Ho AD, Marciniak-Czochra A (2018) Mathematical modeling of the impact of cytokine response of acute myeloid leukemia cells on patient prognosis. Sci Rep 8(1):2809. https:\/\/doi.org\/10.1038\/s41598-018-21115-4","journal-title":"Sci Rep"},{"issue":"7","key":"5115_CR22","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1182\/blood-2011-04-349258","volume":"118","author":"X Thomas","year":"2011","unstructured":"Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terr\u00e9 C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis J-H, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H (2011) Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 118(7):1754\u20131762. https:\/\/doi.org\/10.1182\/blood-2011-04-349258","journal-title":"Blood"},{"issue":"408","key":"5115_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2307\/2290084","volume":"84","author":"LJ Wei","year":"1989","unstructured":"Wei LJ, Lin DY, Weissfeld L (1989) Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 84(408):1065\u20131073. https:\/\/doi.org\/10.2307\/2290084. arXiv:2290084","journal-title":"J Am Stat Assoc"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05115-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T13:06:00Z","timestamp":1697893560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05115-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":23,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5115"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05115-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DM consults for Abbvie, Beigene, BMS, Gilead, Janssen, Novartis, and Takeda. HD consults Abbvie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, Bristol Myers Squibb, Celgene, Daiichi Sankyo, GEMoaB, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Servier, Stemline, and Syndax. His institute has been receiving support from Abbvie, Agios, Amgen, Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, Kronos-Bio, Novartis, and Pfizer. CR is on the advisory boards of Abbvie, Astellas, BMS, Jazz Pharma, Novartis, Servier, and Takeda; his institution is supported by Abbvie, Astellas, BMS, Jazz Pharmaceuticals, and Iqvia. PYD consults for Daiichi-Sankyo, Jazz Pharmaceutical, Astellas, Abbvie, BMS, Janssen, and Novartis; his institution is supported by Astellas, Roche, Gilead, Daiichi-Sankyo, BMS, Servier, and Novartis. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}